Belatacept for first-time heart transplant recipients
Treatments studied
Part of Heart & circulation clinical trials.
This trial studies whether belatacept, an anti-rejection medicine given by IV, can work for people receiving their first heart transplant. It aims to see if it prevents rejection safely for patients and whether it fits better than standard approaches for certain candidates.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old, and you’re able to take medicine by mouth and follow the IV schedule
- You are waiting for your first (primary) heart transplant and are listed only for a heart transplant
- You must test positive for EBV (a common virus; blood test shows past exposure)
- You must not have had prior organ transplants or “desensitization” treatment to reduce transplant rejection risk
- Kidney and blood tests need to meet minimum levels (kidney function not too low, and enough platelets and neutrophils)
- You must have no signs of active infection (including HIV, hepatitis B/C, and untreated tuberculosis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether Thymoglobulin® is safe and how well it works in people getting their first heart transplant. It may help doctors fine-tune medicines used to prevent the body from rejecting the new heart.
This early-phase study tests a cell treatment (Treg cells made from a child’s thymus tissue) to help prevent the body from rejecting a new heart. It may help reduce rejection risk, but it is experimental and involves added risks and follow-up.
This trial tests a combination of medicines (post-transplant cyclophosphamide, bortezomib, and abatacept) to lower your chance of developing graft-versus-host disease (when transplanted immune cells attack your body) after a transplant. If you qualify, you’ll receive the study medicines as part of your post-transplant care and be followed closely to check safety and prevention of GvHD.
This study tests a drug called belatacept, which may help prevent the body from rejecting a new heart. It is given after a heart transplant, and the goal is to see if it works as well as or better than standard anti-rejection medicines.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
This study tests a new approach to managing anti-rejection medicines after a heart transplant. It uses special blood tests to see if your immune system is calm, so doctors can safely reduce the medicines and lower side effects.
Hear when a new Heart Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.